Long COVID Clinical Trial
Official title:
Water-based Activity to Enhance Recovery in Long COVID
This two-year study will evaluate the feasibility and safety of an exercise + cognitive training program to improve neurological symptoms of long-COVID. This is a two-phased trial: 1) an exercise phase and 2) a cognitive training phase. The exercise phase will be an aquatic based exercise program. A combination exercise + memory training programs designed for persons with cognitive impairment have significantly improved memory more than other single intervention groups (exercise only, cognitive training only) and given the success of combination training programs with healthy adults, it is important to adapt these programs for persons with neurological symptoms of long-COVID.
| Status | Not yet recruiting |
| Enrollment | 50 |
| Est. completion date | December 31, 2025 |
| Est. primary completion date | December 31, 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 89 Years |
| Eligibility | Inclusion Criteria: - Veterans, age 18 to 89, of any racial or ethnic group - Previous COVID-19 infection at least 6 months after diagnosis documented in clinical record - Persistent neurological symptoms (e.g., "brain fog", cognitive impairment) occurring within 3 months of onset of COVID-19 infection and lasting at least 8 weeks in duration - Visual and auditory acuity to allow neuropsychological testing - Willingness to participate in clinical trial for 8 months - Approval by Primary Care Provider to participate in water-based physical exercise Exclusion Criteria: Psychiatric Exclusions - Current, uncontrolled severe psychotic disorder determined by the Mini International Neuropsychiatric Interview (MINI) Medical Exclusions - History of neurological (e.g., multiple sclerosis, seizure disorder, stroke,) neurodegenerative (e.g., Parkinson's disease, Alzheimer's disease) or system illness affecting CNS function (e.g., liver failure, kidney failure, congestive heart failure, systemic cancer) occurring before COVID-19 diagnosis - Current severe cardiac disease (e.g., uncontrolled atrial fibrillation, defined as mean 24 hour heart rate >85 beats/min, or 24 hour maximal ventricular rate >150 beats/min; uncontrolled ventricular arrhythmias, defined as recurrent ventricular tachycardia >3 beats in succession, or 24 hour PVC count >20%; active pericarditis or myocarditis; Class III/IV heart failure and / or ejection fraction < 20%; thrombophlebitis; pulmonary disease with a drop in O2 Sat with exercise to 90% without oxygen; embolism within past 6 months) - Inability to participate in an exercise stress test - Inability to read, verbalize understanding and voluntarily sign the Informed Consent |
| Country | Name | City | State |
|---|---|---|---|
| United States | VA Palo Alto Health Care System, Palo Alto, CA | Palo Alto | California |
| Lead Sponsor | Collaborator |
|---|---|
| VA Office of Research and Development |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Feasibility of Intervention Measure | The FIM is a brief measure of the feasibility of an intervention. | At the end of study completion, an average of 8 months | |
| Secondary | Acceptability of Intervention Measure | The AIM is a brief measure that assesses the acceptability of an intervention. | At the end of study completion, an average of 8 months | |
| Secondary | Change in Fatigue Severity Scale | The Fatigue Severity Scale (FSS) is a method of evaluating the impact of fatigue on a person. The FSS is a short questionnaire that requires a person to rate his/her level of fatigue using a scale of 1 (completely disagree) to 7 (completely agree). Scores range from 9 to 63 with higher scores indicating greater fatigue severity. | Through study completion, an average of 8 months | |
| Secondary | Change in Mental Fatigue Scale | The Mental Fatigue Scale (MFS) is self-report scale that includes 15 questions which assess mental fatigue. Items are rated on a scale that ranges from 0 (normal function) to 3 (serious problems). Higher scores indicate greater symptom severity. | Through study completion, an average of 8 months | |
| Secondary | Change in Digit Span | The Digit Span subt-test of the WAIS-IV assesses attention and working memory. | Through study completion, an average of 8 months | |
| Secondary | Change in Digit Symbol Substitution Test | The Digit Symbol Substitution Test from the WAIS-III assesses attention, processing speed and executive function. | Through study completion, an average of 8 months | |
| Secondary | Change in Stroop Color Word Test | The Stroop Color Word test assesses selection attention, cognitive inhibition, and processing speed. | Through study completion, an average of 8 months | |
| Secondary | Change in Rey Auditory Verbal Learning Test | The Rey Auditory Verbal Learning Test; (RAVLT) assesses learning and memory. | Through study completion, an average of 8 months | |
| Secondary | Change in NIH Toolbox Cognitive Battery | The NIH Toolbox is a computerized battery of test that assesses neuropsychological function. | Through study completion, an average of 8 months | |
| Secondary | Change in Hospital Anxiety and Depression Scale | The Hospital Anxiety and Depression Scale (HADS) is a 14-time self-rating scale to assess psychological distress in non-psychiatric patients. Items are rated on a 4-point Likert scale (range 0-3). The total score ranges from 0 to 42 with higher indicating greater severity. | Through study completion, an average of 8 months | |
| Secondary | Change in World Health Organization Disability assessment scale 2.0 | The World Health Organization Disability assessment scale 2.0 (WHODAS 2.0) assesses multiple domains of function including: cognition, mobility, self-care, getting along, life activities (household and work) and participation. | Through study completion, an average of 8 months | |
| Secondary | Change in Canadian Occupation Performance Measure | The Canadian Occupation Performance Measure (COPM) assesses an individual's perceived occupational performance in the areas of self-care, productivity, and leisure. | Through study completion, an average of 8 months | |
| Secondary | Change in Blood labs | Standard blood labs include C-Reactive Protein, Interleukin-6, metabolic panel, and lipid panels | Through study completion, an average of 8 months | |
| Secondary | Genetic Testing | Genetic testing includes assessment of APOE and BDNF genotypes. | Baseline |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05926505 -
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Completed |
NCT05552612 -
Health-related Quality of Life and Long COVID
|
||
| Completed |
NCT05531019 -
COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A
|
N/A | |
| Not yet recruiting |
NCT04949386 -
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
|
Phase 2 | |
| Recruiting |
NCT06118112 -
Living With Long COVID: LONGCOVID-EXPERIENCE
|
||
| Completed |
NCT05185674 -
Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
|
||
| Active, not recruiting |
NCT05965739 -
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
|
N/A | |
| Active, not recruiting |
NCT05965752 -
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
|
N/A | |
| Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
| Recruiting |
NCT05606211 -
Pain in Long COVID-19: The Role of Sleep
|
||
| Active, not recruiting |
NCT05713266 -
Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
|
||
| Completed |
NCT05601180 -
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
|
N/A | |
| Completed |
NCT05679505 -
Vagus Nerve Stimulation for Post-COVID Syndrome
|
N/A | |
| Not yet recruiting |
NCT06045338 -
Mind Body Intervention for Long COVID
|
N/A | |
| Recruiting |
NCT06091358 -
Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.
|
N/A | |
| Recruiting |
NCT05566392 -
Longterm Influence of Pediatric Long COVID Syndrome
|
||
| Recruiting |
NCT05855369 -
Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05572346 -
Digital App for Telerehabilitation in Respiratory Diseases
|
||
| Recruiting |
NCT06316843 -
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
|
Phase 2 |